Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.

被引：0
|
作者：
Baillie, GM [1 ]
Ashcraft, EE [1 ]
Taber, DJ [1 ]
Stone, SS [1 ]
Emovon, O [1 ]
Rogers, J [1 ]
Afzal, F [1 ]
Lin, A [1 ]
Rajagopalan, PR [1 ]
Baliga, PK [1 ]
Chavin, KD [1 ]
机构：
[1] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：377A / 377A
页数：1
相关论文
共 50 条
  • [31] Ten Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients.
    El Hajj, S.
    Azzi, J.
    Kim, M.
    Gabardi, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 948 - 948
  • [32] Comparison of valganciclovir and oral ganciclovir for cytomegalovirus prophylaxis in solid organ transplant recipients.
    Kraman, AA
    Hardwick, LL
    Filo, RS
    Govani, MV
    Milgrom, ML
    Tector, AJ
    Pescovitz, MD
    PHARMACOTHERAPY, 2002, 22 (10): : 1370 - 1370
  • [33] Epidemiology of CMV Disease in CMV-Naive Lung Transplant Recipients in the Era of Valganciclovir Prophylaxis.
    Mitsani, D.
    Vadnerkar, A.
    Silveira, F.
    Celik, U.
    Pilewski, J.
    Crespo, M.
    Nguyen, M. H.
    Clancy, C. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 291 - 291
  • [34] Incidence of CMV with dual therapy prophylaxis in orthotopic liver transplant recipients.
    Ashcraft, EE
    Baillie, GM
    Polito, CC
    Buchanan, EP
    Rodwell, D
    Brown, E
    Rogers, J
    Lin, A
    Baliga, PK
    Chavin, KD
    HEPATOLOGY, 2002, 36 (04) : 661A - 661A
  • [35] Comparison of CMV prophylaxis and preemptive therapy in liver and kidney transplant recipients.
    Taber, DJ
    Dupuis, RE
    Hollar, KD
    Meehan, A
    Rodegast, B
    Salm, J
    Zacks, S
    Shrestha, R
    Gerber, D
    Johnson, MW
    TRANSPLANTATION, 2000, 69 (08) : S181 - S181
  • [36] An RCT of ganciclovir prophylaxis for CMV disease in pediatric liver transplant recipients.
    King, SM
    Superina, R
    Andrews, W
    Winston, D
    Dunn, S
    Colombani, P
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 243 - 243
  • [37] Valganciclovir followed by CMV hyperimmune globulin compared to valganciclovir for 200 days in abdominal organ transplant recipients at high risk for CMV infection.
    Fleming, James
    Taber, Dave
    Pilch, Nicole
    Nadig, Satish
    McGillicuddy, John
    Bratton, Charles
    Baliga, Prabhakar
    Chavin, Kenneth D.
    PHARMACOTHERAPY, 2016, 36 (12): : E307 - E307
  • [38] Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
    Johansson, Inger
    Martensson, Gunnar
    Nystrom, Ulla
    Nasic, Salmir
    Andersson, Rune
    BMC INFECTIOUS DISEASES, 2013, 13
  • [39] Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: Is it effective?
    Goral, S
    Ynares, C
    Dummer, S
    Helderman, JH
    KIDNEY INTERNATIONAL, 1996, 50 : S62 - S65
  • [40] Valganciclovir is safe and effective for CMV prophylaxis in kidney and pancreas transplant recipients who receive antilymphocyte antibody therapy.
    Baillie, GM
    Ashcraft, E
    Taber, D
    Afzal, F
    Rogers, J
    Lin, A
    Emovon, O
    Rajagopalan, PR
    Baliga, P
    Chavin, K
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 426A - 426A
12345